Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.62 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.62 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 17/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | JAK1 | P23458 | 9/20 | 0.54 |
| ▸ | JAK3 | P52333 | 5/20 | 0.54 |
| ▸ | TYK2 | P29597 | 3/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 3/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589328 | 1.00 | AURKA (0.62) | AURKAAURKBINCENPTPX2JAK2 | |
| SCHEMBL13695723 | 0.82 | JAK2 (0.65) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL13695654 | 0.82 | JAK2 (0.60) | AURKAAURKBJAK2HDAC6HDAC1 | |
| SCHEMBL13774665 | 0.82 | JAK2 (0.61) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL20908684 | 0.80 | JAK2 (0.69) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL18555662 | 0.80 | TTK (0.55) | AURKAAURKBINCENPTPX2LRRK2 | |
| SCHEMBL28119090 | 0.80 | JAK2 (0.58) | AURKAAURKBJAK2HDAC6HDAC1 | |
| SCHEMBL3377808 | 0.80 | JAK2 (0.50) | AURKAAURKBJAK2HDAC6HDAC1 | |
| SCHEMBL13695724 | 0.79 | JAK2 (0.62) | AURKAAURKBJAK2HDAC6HDAC1 | |
| SCHEMBL98675 | 0.79 | JAK2 (0.65) | AURKAAURKBJAK2HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3466953-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2021-02-03 | — | — | EP | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| EP-2343298-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-8741912-B2 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-12-13 | — | — | US | disclosed |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-12-13 | — | — | US | disclosed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | AURKA 485/4885AURKB 198/4885INCENP 4449/4885 |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | AURKA 485/4885AURKB 198/4885INCENP 4449/4885 |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | AURKA 485/4885AURKB 198/4885INCENP 4449/4885 |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | AURKA 289/4885AURKB 455/4885INCENP 2154/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | AURKA 485/4885AURKB 198/4885INCENP 4449/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | AURKA 485/4885AURKB 198/4885INCENP 4449/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | AURKA 485/4885AURKB 198/4885INCENP 4449/4885 |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | JAK3, JAK1, JAK2 | AURKA 485/4885AURKB 198/4885INCENP 4449/4885 |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | AURKA 289/4885AURKB 455/4885INCENP 2154/4885 |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | AURKA 289/4885AURKB 455/4885INCENP 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.